Close
Close

Anti-IL13Rα2 (IL13 mutein ((E13Y))-CD86+FcγRI CAR THP1 (CARTHP-W0986)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The anti-IL13Rα2 chimeric antigen receptor (CAR) THP1 cell line is a stable cell line developed using anti-IL13Rα2 CAR lentivirus transfection. This transfected CAR lentiviral vector is constructed to express a scfv of anti-IL13Rα2 antibody (IL13 mutein ((E13Y)) linked to CD86+FcγRI signaling domains.The anti-IL13Rα2 CAR engineered THP1 cells can be used to be differentiated into macrophage cells for in vitro or in vivo phagocytosis studies. This CAR-THP1 cell line product can be used for the researches of Glioma, GBM.

Specific Inquiry

  • Size:
  • Marker:
  • Positive rate:
  Add to Cart

Details

  • Target
  • IL13Rα2
  • Cell Type
  • THP1
  • Cell Background
  • THP-1 is a human leukemia monocytic cell line, which has been extensively used to study monocyte/macrophage functions, mechanisms, signaling pathways, and nutrient and drug transport. This cell line has become a common model to estimate modulation of monocyte and macrophage activities. CAR engineered THP1 cells can be differentiated into macrophages using PMA (Phorbol 12-myristate 13-acetate). Once differentiated (M0 macrophages), they were incubated with IL-4 and IL-13 in order to obtain M2 polarized macrophages or with IFN-gamma and LPS for classical macrophage activation (M1).
  • Targeting Diseases
  • Glioma, GBM
  • CAR Expression
  • Positive
  • CAR Positive Rate
  • >95% for stable cell pool (please submit an inquiry if single clonal cell line is needed.)
  • Cell Viability
  • >90%
  • Mycoplasma Testing
  • Negative
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Safety Consideration
  • Biosafety Level 1
  • Restriction
  • Research use only
  • Size
  • 2 million cells*2 vials
  • Storage
  • Frozen cells should be stored in a liquid nitrogen tank (-150°C~-190°C) for long term.

CAR Components

  • Promoter
  • EF1a
  • scFv
  • IL13 mutein ((E13Y)
  • Hinge
  • CD8
  • TM
  • CD8
  • ICD
  • CD86+FcγRI
  • Marker
  • GFP or N/A
  • Receptor Construction
  • scFv-hinge(CD8)-TM(CD8)-ICD(CD86+FcγRI)
  • Discription of Signaling Cassetes
  • The cytoplasmic portion of the human CD86 (amino acids 269-329) plus the cytoplasmic part of the human FcγRI (amino acids 314-374) are used as the CAR intracellular signaling domains.
    CD86:
    Receptor involved in the costimulatory signal essential for T-lymphocyte proliferation and interleukin-2 production, by binding CD28 or CTLA-4. May play a critical role in the early events of T-cell activation and costimulation of naive T-cells, such as deciding between immunity and anergy that is made by T-cells within 24 hours after activation.

    FcγRI:
    This protein is a high-affinity Fc-gamma receptor, and plays an important role in the immune response. As a member of the immunoglobulin superfamily (it has two Ig-like domains), FcγRI is expressed on macrophage and other cells, controlling the production of important immune mediators called cytokines that promote inflammation. Fc gamma receptors belong to the group of non-catalytic tyrosine-phosphorylated receptors which share a similar signalling pathway involving phosphorylation of tyrosine residues. The receptors generate signals within their cells through an important activation motif known as an immunoreceptor tyrosine-based activation motif (ITAM). An ITAM is present in the intracellular tail of FcγRIIA, and its phosphorylation induces phagocytosis in macrophages. FcγRI and FcγRIIIA do not have an ITAM but can transmit an activating signal to their phagocytes by interacting with another protein that does. This adaptor protein is called the Fcγ subunit and, like FcγRIIA, contains the two YXXL sequences that are characteristic of an ITAM.

Target

  • Target
  • IL13Rα2
  • Target Species
  • Human
  • Clone
  • IL13 mutein ((E13Y)
  • Host
  • Human
  • Gene Name
  • Interleukin 13 receptor subunit alpha 2
  • Introduction
  • The protein encoded by this gene is closely related to Il13RA1, a subuint of the interleukin 13 receptor complex. This protein binds IL13 with high affinity, but lacks cytoplasmic domain, and does not appear to function as a signal mediator. It is reported to play a role in the internalization of IL13.
  • Alternative Names
  • CT19; IL-13R; IL13BP; CD213A2; IL13RA2; Interleukin 13 receptor subunit alpha 2; IL13Rα2

Customize Your CAR Products

Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-IL13Rα2 (IL13 mutein ((E13Y)) ICD(CD86+FcγRI) CAR THP1 Cell Line (CARTHP-W0986). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR Vector Products

CAR Animal Cells

CAR Cell Products

CAR-MA Vector Products

CAR Viral Particles

CAR-MA Cell Products

CAR mRNA

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout